hiv 1 nef in 1

HIV-1 Nef-IN-1 is an inhibitor of the HIV-1 Nef protein, effectively competing for Nef-SH3Hck interactions (Kd: 6.7 μM).

Hck-IN-1 is a selective Nef-dependent Hck inhibitor (IC50s: 2.8 μM and >20 μM for Nef:Hck complex and Hck) with antiretroviral activity. Hck-IN-1 is a direct and wide HIV-1 Nef antagonist with an IC50 of 100-300 nM for wild-type HIV-1 replication.

FC-14369 is a PROTAC degrader targeting the HIV-1Nef protein (HIV-1Nef protein) with a DC50 value of 160 nM. By means of its bifunctional structure, FC-14369 binds to both Nef and Cereblon E3 ubiquitin ligase, facilitating Nef ubiquitination and proteasomal degradation. This action restores the expression of cell surface CD4 and MHC-I, thereby inhibiting HIV-1 replication. FC-14369 is applicable in the study of HIV infection and AIDS.

Tat-beclin 1scrambled is the disordered segment and control of Tat-beclin 1, derived from a region of the autophagy protein beclin 1. Beclin 1 induces autophagy by interacting with HIV-1Nef and the autophagy inhibitory factor GAPR-1 (GLIPR2). Tat-beclin 1 decreases both the accumulation of polyglutamine-expanded protein aggregates and the replication of several pathogens, such as HIV. Additionally, Tat-beclin 1 reduces mortality rates in mice infected with chikungunya or West Nile virus.

Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis (apoptosis) inducer derived from the myristoylated protein encoded by the HIV nef gene. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT) by activating the apoptotic pathway through increased levels of caspase-3 in cancer cells. Additionally, it suppresses VEGF-A, p-GSK-3β, and vimentin while enhancing E-cadherin, thereby hindering angiogenesis and EMT processes. Nef-M1 is applicable in colorectal cancer and breast cancer research.